Allergan IncAGN:NYQ

133.92
2.46 / 1.87%
5.09m
18.53%
0.7537
Close in USDToday's changeShares traded1 year changeBeta
As of Apr 17 2014 21:00 BST.Data delayed by at least 15 minutes.

Summary

Allergan Inc (AGN:NYQ) set a new 52-week high during Thursday's trading session when it reached 134.41. Over this period, the share price is up 17.74%.

52-week range
Today
81.33
Jun 24 2013
134.41
Apr 17 2014
Open130.38
Day high134.41
Day low129.20
Bid--
Offer--
Previous close131.46
Average volume4.52m
Shares outstanding299.11m
Free float298.57m
P/E (TTM)31.84
Market cap40.06bn USD
EPS (TTM)4.21 USD
Annual div (TTM)0.20 USD
Annual div yield (TTM)0.15%
Div ex-dateFeb 26 2014
Div pay-dateMar 21 2014

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Allergan Inc+14.82 %+3.09 %+47.67 %+18.53 %+170.60 %
S&P 500 INDEX+1.73 %+0.32 %+7.60 %+20.16 %+114.45 %
USA/HEALTH CARE+2.09 %-4.86 %+7.40 %+17.78 %--
USA/PHARMACEUTICALS+2.30 %-2.20 %+9.14 %+14.22 %--
As of Apr 17 2014 21:00 BST.Data delayed by at least 15 minutes.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.